IP Library Granted Patent US 11,173,148
Granted Patent B2
US 11,173,148 · App. 16/867,773 · Granted Nov 16, 2021

Zero-order release preparation composition for animals

Inventor: Teruaki Kuriyama (Higashiosaka, JP)
Assignee: DS PHARMA ANIMAL HEALTH CO., LTD.
A61K31/423A61K9/0002A61K9/2018A61K9/2054A61K47/12A61K47/14A61K47/26A61K47/36A61K47/44A61P25/08A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,173,148
App. No.
16/867,773
Granted
Nov 16, 2021
Kind
B2
Abstract

The present invention relates to a sustained-release pharmaceutical composition intended for animal use, which comprises a drug, a sugar, a wax, and a water-soluble polymer.

Claims (14)

1. A method of treating epilepsy in a dog or cat, comprising administering a zero-order release composition to the dog or cat,

wherein the zero-order release composition comprises (i) zonisamide, (ii) a sugar, (iii) a wax, and (iv) a water-soluble polymer, wherein

(i) the content of zonisamide is 20 wt %-70 wt %,

(ii) the sugar is at least one selected from the group consisting of isomalt, mannitol, lactose, sucrose, glucose, and sorbitol, and the content of the sugar is 15 wt %-70 wt %,

(iii) the wax is at least one selected from the group consisting of hydrogenated castor oil, hydrogenated rapeseed oil, carnauba wax, stearic acid, and sodium stearyl fumarate, and the content of the wax is 1.5 wt %-50 wt %,

(iv) the water-soluble polymer is at least one selected from the group consisting of gum arabic, xanthane gum, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), and methylcellulose (MC), and the content of the water-soluble polymer is 6 wt %-60 wt %, and

wherein the method obtains a zero-order release dissolution rate and obtains complete dissolution at about 3 hours.

2. The method according to claim 1 , wherein

(ii) the sugar is at least one selected from the group consisting of isomalt, mannitol, and lactose,

(iii) the wax is at least one selected from the group consisting of hydrogenated castor oil, carnauba wax, stearic acid, and sodium stearyl fumarate,

(iv) the water-soluble polymer is at least one selected from the group consisting of gum arabic and hydroxypropylcellulose (HPC).

3. The method according to claim 1 , wherein the zero-order release composition is in the form of a tablet.

4. The method according to claim 1 , wherein (ii) the sugar is isomalt.

5. The method according to claim 1 , wherein (iv) the water-soluble polymer is at least one selected from the group consisting of gum arabic and hydroxypropylcellulose (HPC).

Assignments (3)
CHANGE OF NAME Recorded Jun 12, 2023
From: SUMITOMO PHARMA ANIMAL HEALTH CO., LTD.
To: BUSSAN ANIMAL HEALTH CO., LTD.
Reel/Frame 063963/0487 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 059854 FRAME 0460. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Aug 1, 2022
From: DS PHARMA ANIMAL HEALTH CO., LTD.
To: SUMITOMO PHARMA ANIMAL HEALTH CO., LTD.
Reel/Frame 060943/0965 →
CHANGE OF NAME Recorded May 4, 2022
From: DS PHARMA ANIMAL HEALTH CO., LTD.
To: SUMITOMO PHARMA ANIMAL HEALTH CO., LTD.
Reel/Frame 059854/0460 →
Priority Claims (1)
JP 2016-115580 · Jun 9, 2016 · national
Continuity (2)
Division 16307544
Related Publication 20200323826A1 · Oct 15, 2020